Lemon Balm for Sleep Quality

Verdict: Weak, conflicted evidence for sleep

Lemon balm shows early, low-quality signs of improving sleep quality, but the evidence is too weak and conflicted to rely on it as a proven sleep aid. The few supportive trials are small, short, and undermined by industry funding and combination formulas.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade rests on just four small, short randomized trials with no meta-analysis or Cochrane review for sleep. The most sleep-specific trial (PMID 39683592, n=30, 2 weeks) reported a meaningful drop in insomnia severity (ISI -2.9 points; 87% vs 30% improved), and a 3-week trial (PMID 37927585, n=100) found better sleep quality and mood. Both, however, tested specific patented phospholipid/phytosome preparations that cannot be generalized to ordinary lemon balm tea or capsules.

The signal weakens on closer inspection. The strongest sleep trial (PMID 39683592) carries a serious conflict of interest: its lead author is the manufacturer's scientific director and the product was co-developed by the sponsor. The insomnia trial (PMID 30591886, n=45) combined lemon balm with Nepeta menthoides, so the benefit cannot be pinned on lemon balm alone, and the menopause trial (PMID 33465795, n=60) measured general quality of life (MENQOL), not a dedicated sleep endpoint.

Authorities add little support. The US FDA lists lemon balm extract only as a GRAS flavoring agent, which is a safety classification rather than an efficacy endorsement, and EFSA, the UK NHS, NIH ODS, Mayo, Harvard, and Cleveland offer no dedicated backing. Sleep-medicine guidelines still place CBT-I as first-line care. There is also a moderate additive-sedation risk if lemon balm is combined with other sedatives or sleep medications.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.53
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.53
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of Melissa officinalis Phytosome on Sleep Quality: A Prospective, Double-Blind, Placebo-Controlled, Cross-Over Study
PMID: 39683592 2024 RCT (double-blind) n = 30
Finding: ISI significantly lower in treated group (6.8 vs 9.7, MD -2.9 points, p=0.003); 87% vs 30% reported improved sleep (p=0.0003).
⚠️ Industry-funded Effect size: MD -2.9 ISI points
View on PubMed
The possible calming effect of subchronic supplementation of a standardised phospholipid carrier-based Melissa officinalis L. extract
PMID: 37927585 2023 RCT (double-blind) n = 100
Finding: Significant improvements in depressive mood, anxiety, stress and affect (all p<0.001); sleep quality improved.
View on PubMed
Effects of Herbal combination (Melissa officinalis L. and Nepeta menthoides) on insomnia severity, anxiety and depression in insomniacs
PMID: 30591886 2018 RCT (double-blind) n = 45
Finding: ISI fell 16.69 to 11.30 in herbal group vs 16.09 to 14.31 in placebo (p=0.008).
🟠 Limited quality Academic Effect size: Between-group ISI improvement ~3.6 points
View on PubMed
The Effectiveness of Melissa Officinalis L. versus Citalopram on Quality of Life of Menopausal Women with Sleep Disorder
PMID: 33465795 2021 RCT (double-blind) n = 60
Finding: M. officinalis improved all MENQOL domains vs citalopram and placebo (p<0.001); sleep not isolated primary endpoint.
🟠 Limited quality Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
BALM LEAVES, EXTRACT (MELISSA OFFICINALIS L.) source↗
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-sleep-quality-INT-lemon-balm-001 繁體中文版 →